Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients by Violi, Francesco et al.
Incidence and Recurrence of Portal Vein
Thrombosis in Cirrhotic Patients
Francesco Violi1 Gino Roberto Corazza2 Stephen H. Caldwell3 Giovanni Talerico1
Giulio Francesco Romiti1 Laura Napoleone1 Francesco Perticone4 Luigi Bolondi5
Antonello Pietrangelo6 Anna Rita Vestri7 Valeria Raparelli1,8 Stefania Basili1 on behalf of PRO-LIVER
Collaborative Group
1 I Clinica Medica, Department of Internal Medicine and Medical
Specialties, Sapienza University of Rome, Rome, Italy
2First Department of Internal Medicine, Fondazione IRCCS Policlinico
San Matteo, University of Pavia, Pavia, Italy
3Division of Gastroenterology and Hepatology, Digestive Health
Center, University of Virginia, Charlottesville, Virginia, United States
4Department of Medical and Surgical Sciences, University of
Catanzaro, Catanzaro, Italy
5Department of Medical and Surgical Sciences, University of Bologna,
Bologna, Italy
6Unit of Internal Medicine 2, Department of Medical and Surgical
Science for Children and Adults, University of Modena and Reggio
Emilia, Modena, Italy
7Department of Public Health and Infectious Disease, Sapienza
University of Rome, Rome, Italy
8Department of Experimental Medicine, Sapienza University of Rome,
Rome, Italy
Thromb Haemost 2018;119:496–499.
Address for correspondence Francesco Violi, MD, I Clinica Medica,
Department of Internal Medicine and Medical Specialties, Sapienza
University of Rome, Viale del Policlinico 155, Rome 00161, Italy
(e-mail: francesco.violi@uniroma1.it).
Cirrhosis has been long considered a risk factor for bleeding
due to the co-existenceof the so-called ‘coagulopathy’.1,2More
recently, however, compelling evidences have been provided
on the occurrence of thrombotic events in the portal and
systemic circulation.3–5 Portal vein thrombosis (PVT) is pre-
dominantly observed in patientswithmoderate to severe liver
failure with a variable prevalence ranging from 0.6 to 25%.6–8
Only fewstudies have provideda longitudinal assessmentof
the PVT incidence and its sequelae, including recurrence and
survival.9–14 Due to the variability of PVT incidence and the
paucity of data regarding recurrence and survival,15–20 we
prospectively analysed the incidence and the recurrence of
PVT in the population of Portal vein thrombosis Relevance On
Livercirrhosis: ItalianVenous thromboticEventsRegistry (PRO-
LIVER), a multi-centre study,8 which involved 43 enrolling
centres in Italy (ClinicalTrials.gov Identifier: NCT01470547).
The presence of PVT at baseline was assessed with Dop-
pler ultrasound examination.
By pre-set study criteria, PVT was first suspected when
solid endoluminalmaterialwas detected in themain trunkof
the portal vein and/or its branches, and it was confirmed by
demonstration of afillingdefect on theDoppler examination.
Occlusive/complete PVT was defined by a thrombus leaving
no channel for blood flow. Otherwise, PVT was considered
non-occlusive/incomplete.
In case of death, the circumstances and likely cause(s)
were recorded.
Survival curves were formally compared using the log-
rank test. Cox proportional hazards analysis was used to
calculate the adjusted relative hazards of outcome events by
each clinical variable.
Stochastic level of entry into the model was set at a p-
value of 0.10, and interaction terms were explored for all the
variables in the final model.
Demographics and clinical characteristics of the popula-
tion have been previously reported.8
Seven hundred and fifty-three cirrhotic patients were
followed up for a median of 21 (interquartile range [IQR]:
6.7–24) months yielding 1,008 patient-years of observation.
 The list of PRO-LIVER Collaborative Group appears in the
Supplementary Appendix.
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During the observational period, 61 (8%) patients devel-
opedPVT (52% symptomatic): 36 (59%) of thesewere free from
PVT at baseline andwere considered as a newevent (15.8 [9.4–
21.0] months), 25 (41%) occurred in patients who displayed
PVT at baseline andwere, thus, classified as a recurrence (16.0
[12.0–24.0] months). The incidence rate of PVT was 6.05 per
100 patient-years in all patients, 4.1 per 100 patient-years in
thosewithout PVTat admissionand18.9per 100patient-years
in those with PVT at admission.
Among the 25 patients who displayed PVT recurrences, 7
(28%) were reported to take anticoagulants (n ¼ 5, 20%) or
anti-platelets (n ¼ 2, 8%) at baseline.
Complete thrombosis was detected in 15 (25%) patients;
as for the location, in 33 (54%) patients PVT occurred only in
the main trunk or one of its branches, while obstruction of
more than one portal vein branches was present in 28 (46%)
patients; an extension of thrombosis to the mesenteric–
splenic veins was reported in 15 (24%) patients.
Table 1 Clinical and laboratory characteristics in cirrhotic patients experienced portal vein thrombosis during the follow-up
Variables Patients without PVT
(N ¼ 692)
Patients with new
incident PVT
(N ¼ 36)
Patients with recurrent PVT
(n ¼ 25)
p-Value
Age (mean  SD), years 64.5  12.1 62.1  13.5 62.1  13.5 0.516
Male sex, n (%)a 463 (67) 31 (86) 19 (76) 0.038
Aetiology 0.651
Alcohol, n (%) 170 (25) 7 (19) 9 (36)
Viral, n (%) 308 (44) 15 (42) 9 (36)
NASH/metabolic, n (%) 40 (6) 2 (6) 1 (4)
Autoimmune, n (%) 17 (2) 0 (0) 1 (4)
Mixed, n (%) 91 (13) 9 (25) 2 (8)
Others/unknown, n (%) 66 (9) 3 (8) 3 (12)
Child–Pugh score 0.314
Class A, n (%) 365 (53) 15 (42) 17 (68)
Class B, n (%) 236 (34) 14 (42) 7 (28)
Class C, n (%) 91 (13) 6 (17) 1 (4)
MELD score, median (IQR) 10 (8–14) 10 (8–14) 11 (8–11) 0.576
Baveno score 0.391
Compensated, n (%) 406 (59) 17 (47) 15 (60)
Decompensated, n (%) 286 (41) 19 (53) 10 (40)
Ascites 0.696
Absent, n (%) 429 (62) 19 (53) 16 (64)
Responsive to diuretic therapy, n (%) 196 (28) 13 (36) 8 (32)
Refractory, n (%) 67 (10) 4 (11) 1 (4)
Encephalopathya 0.044
Absent, n (%) 590 (85) 24 (69) 22 (88)
Mild, n (%) 90 (13) 11 (31) 3 (12)
Moderate to severe, n (%) 12 (2) 1 (3) 0 (0)
HCC, n (%) 139 (20) 9 (25) 4 (16) 0.672
Albumin, (gr/L) 3.4  0.6 3.5  0.7 3.4  0.4 0.752
Bilirubin, (mg/dL) 2.2  3.3 2.4  3.8 1.2  0.5 0.287
PT-INR 1.30  0.34 1.33  0.22 1.28  0.17 0.818
Serum creatinine (mg/dL) 0.95  0.64 0.92  0.42 0.93  0.27 0.933
Platelet count (103/L)b 116  66 82  43 88  44 0.001
Platelet count tertilesa
 126 (103/L) 240 (35) 5 (14) 5 (20) 0.001
76–125 (103/L) 240 (35) 9 (25) 7 (28)
 75 (103/L) 212 (30) 22 (61) 13 (52)
Abbreviations: HCC, hepatocellular carcinoma; IQR, interquartile range; MELD score, Model for End-stage Liver Disease score; NASH, non-alcoholic
steatohepatitis; PT-INR, prothrombin time-international normalized ratio; PVT, portal vein thrombosis; SD, standard deviation.
aChi-square trend.
bAnalysis of variance.
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►Table 1 reports the clinical characteristics of the patients
according to the presence or not of PVT during the follow-up
period; patients experiencing PVT had lower platelet count
and previous PVT.
Cox multivariable model showed that previous PVT
(hazard ratio [HR]: 4.22, 95% confidence interval [CI]:
2.49–7.15, p < 0.001) (►Fig. 1A) and being in the third lower
tertile of platelets count (vs. thefirst) (HR: 3.52, 95% CI: 1.71–
7.23, p ¼ 0.001) were significantly and independently asso-
ciated with the occurrence of PVT.
During the study, 145 (19%) died (median [IQR] follow-
up ¼ 9.87 [3.6–16.3]months). Multivariablemodels demon-
strated that only age (HR: 1.03, 95% CI: 1.02–1.05, p < 0.001),
hepatocellular carcinoma (HR: 2.11, 95% CI: 1.49–2.98,
p < 0.001), Child–Pugh classes B (HR: 5.61, 95% CI: 3.60–
8.75, p < 0.001) and C (HR: 11.46, 95% CI: 6.95–18.88,
Fig. 1 (A) Survival free from portal vein thrombosis (PVT) in patients according to previous PVT at admission. Log-rank: 53.342; p < 0.001.
(B) Cumulative survival according to previous PVT at admission. Log-rank: 37.578; p < 0.001.
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p < 0.001) and PVT at the entry (HR: 1.70, 95% CI: 1.18–2.45,
p ¼ 0.004) (►Fig. 1B) remained statistically significant as
independent predictors of death.
This study shows that in cirrhosis PVT is a risk factor for
PVT recurrence and low survival.
Previous analysis of PVT incidence in cirrhotic population
was limited to patients with low to moderate cirrhosis and it
was associated to an annual risk in average of 2%.9 In this study,
including patients with low to severe cirrhosis, the annual PVT
incidence rate was 6.05%. This incidence, however, changes
when a previous PVT is reported at the admission. Thus, the
annual rateofPVTwasmuchhigher inpatientswith ahistoryof
PVT indicating that PVTper se carries a risk for recurrences. It is
noteworthy that in the multivariable regression analysis, not
only previous PVT, but also low platelet count independently
predicted the occurrence of PVT event. This paradoxical asso-
ciation could reflect the platelet over-activation and consump-
tion and consequent low platelet count due to a rapid platelet
turnover.21
During the follow-up, the survival rate ofour populationwas
80.7%,which isconsistentwithother reportsonthissetting.11,20
In addition to the known association between hepatocellular
carcinoma and liver failure versus low survival, we found that
PVT at entry was per se an independent predictor of low
survival. However, we have no element to suggest that PVT is
a factor favouring low survival or is amere reflection of disease
severity as data regarding themortality causewere incomplete.
The studyhas implicationsand limitations. The study shows
that cirrhosis is complicated by a high rate of PVT and that
previous PVT is an independent predictor not only of PVT
recurrencebut alsoof lowsurvival. The studyopenspotentially
novel therapeutic scenarios as the association between PVT
and poor outcomes would provide a rationale to plan inter-
ventional trials with anti-thrombotic drugs. A recent meta-
analysis on this topic22 suggested a potential usefulness of
anticoagulants in improving outcomes of PVT but randomized
controlled trials arenecessary to support thisfinding. ThePRO-
LIVER study has been performed in a single country, enrolling
only Caucasians, limiting the generalizability of the findings to
cirrhotic patients from other countries or ethnic groups.
In conclusion, PVT is a frequent complication of cirrhosis
and its early diagnosis would be helpful to identify patients
at risk of poor clinical outcomes.
Conflict of Interest
None declared.
References
1 Tripodi A, Mannucci PM. The coagulopathy of chronic liver dis-
ease. N Engl J Med 2011;365(02):147–156
2 Violi F. Should the term coagulopathy in cirrhosis be abandoned?
JAMA Intern Med 2015;175(05):862–863
3 Lisman T, Violi F. Cirrhosis as a risk factor for venous thrombosis.
Thromb Haemost 2017;117(01):3–5
4 Ferro D, Angelico F, Caldwell SH, Violi F. Bleeding and thrombosis
in cirrhotic patients: what really matters? Dig Liver Dis 2012;44
(04):275–279
5 Ambrosino P, Tarantino L, Di Minno G, et al. The risk of venous
thromboembolism in patients with cirrhosis. A systematic review
and meta-analysis. Thromb Haemost 2017;117(01):139–148
6 Amitrano L, GuardascioneMA, Brancaccio V, et al. Risk factors and
clinical presentation of portal vein thrombosis in patients with
liver cirrhosis. J Hepatol 2004;40(05):736–741
7 Fimognari FL, Violi F. Portal vein thrombosis in liver cirrhosis.
Intern Emerg Med 2008;3(03):213–218
8 Violi F,CorazzaGR,Caldwell SH,etal;PRO-LIVERCollaborators. Portal
vein thrombosis relevance on liver cirrhosis: Italian Venous Throm-
botic Events Registry. Intern Emerg Med 2016;11(08):1059–1066
9 Nery F, Chevret S, Condat B, et al; Groupe d’Etude et de Traitement
du Carcinome Hépatocellulaire. Causes and consequences of
portal vein thrombosis in 1,243 patients with cirrhosis: results
of a longitudinal study. Hepatology 2015;61(02):660–667
10 Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis
in candidates for liver transplantation: usefulness of screening
and anticoagulation. Gut 2005;54(05):691–697
11 MaruyamaH,OkugawaH, TakahashiM, YokosukaO. Denovo portal
vein thrombosis in virus-related cirrhosis: predictive factors and
long-term outcomes. Am J Gastroenterol 2013;108(04):568–574
12 Zocco MA, Di Stasio E, De Cristofaro R, et al. Thrombotic risk
factors in patients with liver cirrhosis: correlation with MELD
scoring system and portal vein thrombosis development. J Hepa-
tol 2009;51(04):682–689
13 Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and
liver transplantation. J Hepatol 2012;57(01):203–212
14 John BV, Konjeti R, Aggarwal A, et al. Impact of untreated portal
vein thrombosis on pre and post liver transplant outcomes in
cirrhosis. Ann Hepatol 2013;12(06):952–958
15 EnglesbeMJ, Kubus J, MuhammadW, et al. Portal vein thrombosis
and survival in patients with cirrhosis. Liver Transpl 2010;16(01):
83–90
16 Ghabril M, Agarwal S, Lacerda M, Chalasani N, Kwo P, Tector AJ.
Portal vein thrombosis is a risk factor for poor early outcomes
after liver transplantation: analysis of risk factors and outcomes
for portal vein thrombosis in waitlisted patients. Transplantation
2016;100(01):126–133
17 Luca A, Caruso S, Milazzo M, et al. Natural course of extrahepatic
nonmalignant partial portal vein thrombosis in patients with
cirrhosis. Radiology 2012;265(01):124–132
18 Stine JG, Shah PM, Cornella SL, et al. Portal vein thrombosis,
mortality and hepatic decompensation in patients with cirrhosis:
a meta-analysis. World J Hepatol 2015;7(27):2774–2780
19 Fujiyama S, Saitoh S, Kawamura Y, et al. Portal vein thrombosis in
liver cirrhosis: incidence, management, and outcome. BMC Gas-
troenterol 2017;17(01):112
20 Berry K, Taylor J, Liou IW, Ioannou GN. Portal vein thrombosis is
not associated with increased mortality among patients with
cirrhosis. Clin Gastroenterol Hepatol 2015;13(03):585–593
21 Violi F, Basili S, Raparelli V, Chowdary P, Gatt A, Burroughs AK.
Patients with liver cirrhosis suffer from primary haemostatic
defects? Fact or fiction?. J Hepatol 2011;55(06):1415–1427
22 Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of anticoagulants
in patients with cirrhosis and portal vein thrombosis: a systema-
tic review and meta-analysis. Gastroenterology 2017;153(02):
480–487
Thrombosis and Haemostasis Vol. 119 No. 3/2018
Letter to the Editor 499
D
ow
nl
oa
de
d 
by
: A
z.
 O
sp
ed
al
ie
ra
. I
st
. O
sp
ita
lie
ri 
Ve
ro
na
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
